



TECHNICAL USE BULLETIN

VectoPrime™

Complete Single-Brood Control

MADE WITH

BioFuse™

TECHNOLOGY

The prime solution for complete single-brood control



Single-brood/floodwater mosquitoes present two complex challenges for abatement districts. First, larvae often hatch and develop at different times and rates, which complicates strategies for treatment timing and larvicide product selection. Second, floodwater habitats can be extremely unpredictable. Flooding patterns can vary greatly based on rain patterns, tidal events, irrigation timing, etc. Consequently, labor-intensive field surveillance is often necessary to identify flooded habitats and dominant life stages present (i.e., from 1st to 4th instar) before larviciding can begin.

In order to address these challenges, Valent Health developed VectoPrime™ Biological Larvicide, a next-generation biorational larvicide for complete single-brood control that can also be applied pre-flood. VectoPrime™ combines *Bti* strain AM65-52 with (S)-methoprene in each micro particle by utilizing Valent Health

BioFuse™ technology. This allows VectoPrime™ to offer the industry's widest single-brood application window (1st to 4th instar, or pre-flood) with the industry's lowest rates for direct application to water, thus saving significant operational costs while improving application flexibility.



Features and Benefits

FEATURES

Biorational larvicide
with highly specific activity against mosquitoes

BioFuse™ technology
(combines the dual modes of action from *Bti* strain AM65-52 and (S)-methoprene into a carefully selected ratio in every micro particle)

Quickly kills mosquito larvae

Controls all mosquito species

Double “plus” potency and higher bulk density

Pre-flood application capacity
in select environments

Standard size granule
(same as VectoBac® GS, VectoLex® FG and VectoMax® FG)

BENEFITS

- Not harmful to non-target populations

- Can treat all larval stages
- Wider application window for early or late instars
- Reduces number and volume of products needed; more warehouse space

- Only mosquito growth regulator formulation where results can be observed within 24 hours in the field (eliminates need to collect pupae to determine efficacy)

- Application flexibility

- Improved payload and lower application rates significantly reduce operational costs

- Reduces need to monitor flooding and wait for expected hatching

- Simplifies aircraft calibration and characterization

History

BUILDING ON MOSQUITO ABATEMENT PROGRAM INSIGHT

Mosquito larviciding in many countries around the globe is generally based on short-residual biorational products using one of two active ingredients: *Bacillus thuringiensis* subsp. *israelensis* or (S)-methoprene. These larvicides can provide cost-effective solutions for control of single-brood floodwater mosquitoes. However, each of these active ingredients delivers optimal activity against different mosquito larval stages. As a result, multiple products are often used to manage changing scenarios.

In addition, many mosquito control programs manage multiple floodwater sites, but they have limited capacity to survey and treat all the sites once they are flooded. By the time many programs can reach a site, the larvae may have already progressed into late instars, and in some cases might have a mix of early and late instars. As a result, some programs have moved to

pre-hatch products that have the residual capacity to treat multiple floods. However, in many cases, residual control of multiple floods is not needed. In these cases, a single, cost effective pre-flood application is sufficient to allow program managers the “breathing room” to focus on more immediate issues. The need for single-brood product flexibility—and the desire of programs to possess dual mode of action solutions—inspired Valent Health to develop a next-generation tool for managing these public health problems.


Valent Health’s experience in developing value-added products with combinations of active ingredients via its proprietary BioFuse™ technology led to the industry’s most flexible mosquito larval control solution for single-brood mosquitoes: **VectoPrime™**.

BioFuse™ Technology



Valent Health's BioFuse™ technology combines *Bti* strain AM65-52 and (S)-methoprene in a specific toxin ratio into every micro particle of VectoPrime™. This technology offers mosquito control professionals the ability to take advantage of each active ingredient's strengths, while significantly reducing the limitations that each possesses.




Single-brood *Bacillus thuringiensis* subsp. *israelensis* (*Bti*) products are most effective against early to mid instar larvae, and (S)-methoprene single-brood products are most effective against mid to late instar larvae (Fig 1). In either case, the most appropriate single-brood active ingredient to be used can be determined only after the habitat is sampled.



BIOFUSE™ PARTICLES SHOWN USING SCANNING ELECTRON MICROSCOPE



Differences in LC50s based on active ingredient and larval instar*:



* All figures extrapolated from the following published literature:

Fig 1, 2, 3: Phoochevin et al. 2008. Effects of cyromazin and methoprene on the developmental stages of *Anopheles sirus*, *Aedes aegypti* and *Culex quinquefasciatus* (Diptera: Culicidae).

Fig 1: Lacey et al. 1988. Host range and selected factors influencing the mosquito larvicidal activity of the PG-14 isolate of *Bacillus thuringiensis* var. *morrisoni*. *J Am Mosq Control Assoc.* 1988 Mar; 4(1): 39-43.

Fig 2: Boeckx et al. 2008. Communications in agricultural and applied biological sciences. Vol 73(3) 349-666.

Fig 3: Nayar et al. 1999. Laboratory evaluation of biotic and abiotic factors that may influence larvicidal activity of *Bacillus thuringiensis* serovar *israelensis* against two Florida mosquito species. *J Am Mosq Control Assoc.* 15(1): 32-42.

Efficacy

By combining *Bti* and (S)-methoprene in a single formulation, VectoPrime™ delivers effective control for multiple target mosquito species throughout all four instars. BioFuse™ technology ensures that each micro particle contains both AIs and they are delivered in appropriate ratios for consistent application and results.


Micro particles are quickly released on contact with water

Quick kills deliver visible proof that larvae are dead

Low application rates due to high potency and dual action

Dual action provides complete control of asynchronous broods

Easy to use—optimized for existing equipment and application strategies



Mode of Action

BACILLUS THURINGIENSIS SUBSP. ISRAELENSIS (STRAIN AM65-52)

Bti is a naturally occurring spore-forming bacterium found in soil and aquatic environments throughout the world. For more than 30 years, *Bti* has played a pivotal role in public health programs by helping to control vector and nuisance insects around the world. Discovered and isolated in the 1970s, *Bti* is proven to be an effective larvicide in the fight against mosquitoes and black flies (*Simulium*) while avoiding harm to non-target populations and the environment.

At the time of sporulation, *Bti* produces complex, highly specific insecticidal crystal proteins known as protoxins. While essentially nontoxic to nearly all forms of life, when these proteins are applied to larval habitats of mosquitoes, the mosquito larvae ingest them by filter feeding. The crystal proteins are solubilized by the alkaline juices in the larval midgut and are cleaved by the midgut proteases, yielding active peptide toxins called delta-endotoxins. The delta-endotoxins cause the formation of holes in the midgut cell wall, leading to lysis of cells and larvae death.


The reason *Bti* has remained effective since its introduction is the synergistic nature of four protein toxins that give *Bti* its efficacy. These four delta-endotoxins belong to three distinct toxin classes, each of which *Bti* releases when ingested by target larvae:

Cyt1A (27 kDa)	Cry4A (134 kDa)
Cry4B (128 kDa)	Cry11A (66 kDa)

While studies in a laboratory setting have shown resistance potential when individual toxins were isolated¹ from a particular strain of *Bti*,² no empirical or operational evidence of resistance has ever been substantiated when using the naturally occurring wild-type *Bti* strain AM65-52—a fact that has been documented by many of the foremost public health scientists in the world.³ For this reason, it is not uncommon to hear *Bti* (including AM65-52) referred to as the single most important active ingredient available for public health larviciding programs.

In addition to the effectiveness of *Bti*, it has an excellent safety record and very low mammalian toxicity: LD50 values for both oral and dermal toxicity are more than 30,000 mg/kg. The mosquitocidal crystal proteins, spores, and vegetative cells of *Bti* administered by different routes have been found to be non-pathogenic and non-toxic to various animal species in maximum challenge tests.⁴ *Bti* has been considered safe for use in aquatic environments, including drinking water reservoirs, for the control of mosquito, black fly and other closely related fly larvae.⁵

ENLARGED SECTION OF MIDGUT



(S)-METHOPRENE


In the mid-1970s, (S)-methoprene became the first successful biorational mosquito larvicide to be used in the U.S. Its excellent safety record, very low mammalian toxicity (LD50 for oral toxicity is more than 34,000 mg/kg), and negligible long-term effects against almost all non-target populations at field rates (USEPA 2001)⁶ resulted in (S)-methoprene-based products becoming a key tool for many mosquito abatement programs across the U.S.

(S)-methoprene is an insect growth regulator that acts as a mimic of the natural juvenile hormone (JH) in mosquitoes. In nature, the JH works together with the molting hormone to determine the outcome of each molt (i.e., growth stage). High concentrations of JH are needed for immature larvae to grow into larger larval stages (instars). Low concentrations of JH are required during the last larval stage (4th instar) prior to the larval-to-pupal molt, and the JH must be essentially zero in the pupae before metamorphosis can occur.

Since JH levels must be extremely low during the late 4th instar for pupation and normal adult emergence to occur, applications (or presence) of (S)-methoprene during the sensitive late 4th instar stage produce morphological abnormalities in the mosquitoes that, in most cases, lead to death during or after metamorphosis. Early instar larvae that are exposed to (S)-methoprene develop normally until they reach the pupal stage. (S)-methoprene has little effect on mosquitoes that have already reached the pupal or adult stage.

Species belonging to the genera *Aedes*, *Ochlerotatus*, and *Anopheles* are the most susceptible to (S)-methoprene, whereas *Culex* species are less sensitive (Jakob 1972, Staal 1975).^{7,8}

JUVENILE HORMONE (JH) LEVEL INTENSITY



¹ Wirth. "Mosquito resistance to bacterial larvicidal toxins." *The Open Toxinology Journal*, 2010, 3:126–140.

² Paul A, et al. "Insecticide resistance in *Culex pipiens* from New York." *Journal of the American Mosquito Control Association*, 2005, 21(3):305–309.

³ Becker N, Ludwig M. "Investigations on possible resistance in *Aedes vexans* field populations after a 10-year application of *Bacillus thuringiensis israelensis*." *Journal of the American Mosquito Control Association*, June 1993, 9(2):221–224.

⁴ Becker N, Petric D, Zgomba M, Boase C, Dahl C, Lane J, and Kaiser A. 2003. *Mosquitoes and their control*. Kluwer Academic; Plenum Publishers, New York: ISBN 0-306-47360-7.

⁵ Lacey LA and Merritt RW. 2003. "The safety of bacterial microbial agents used for black fly and mosquito control in aquatic environments." In: *Environmental Impacts of Microbial Insecticides: Need and Methods for Risk Assessment* (HMT Hokkanen and AE Hajek, eds.), pp 151–168. Kluwer Academic Publishers Dordrecht, The Netherlands.

⁶ U.S. Environmental Protection Agency. 2001. Update of the March 1991 methoprene R.E.D. fact sheet. Available from U.S. Environmental Protection Agency, Washington, DC. http://www.epa.gov/pesticides/biopesticides/ingredients/factsheets/factsheet_105401.pdf


⁷ Jakob WL. 1972. Additional studies with juvenile hormone-type compounds against mosquito larvae. *Mosq News* 32:592-595.

⁸ Staal GB. 1975. Insect growth regulators with juvenile hormone activity. *Ann Rev Entomol* 20:417-460.

Flexibility

VectoPrime™ offers abatement professionals superior operational flexibility with a wider application window across all instars and pre-flood. The ability to apply VectoPrime™ prior to flooding means you can plan ahead instead of having to react to changing environmental conditions, saving time and freeing up resources that would have been required for additional field surveillance and additional treatments. In addition, working with a single solution that kills all larval instars also allows you to streamline inventories and simplify replenishment.

In other words, you can start and end your week with the same solution.



Efficiency

With its revolutionary double “plus” *Bti* potency formulation and higher bulk density, VectoPrime™ can cut application rates in half for direct applications to water compared to current single-brood products, delivering more value per acre than conventional single-brood options. By doubling the effectiveness of every payload, you can save on fuel, maintenance, and labor costs.

The industry-standard granule size (same size as VectoBac® GS, VectoLex® FG and VectoMax® FG) streamlines calibration and characterization of application equipment. And the unique combination of AIs means you need only perform calibration and characterization once for your single-brood habitats. In addition, VectoPrime™ granules are non-abrasive, reducing attrition to application equipment when compared to sand-based products.



VectoBac® GS



VectoLex® FG



VectoMax® FG



VectoPrime™ FG

To learn more about **VectoPrime™**,
scan the following **QR code**:



VALENT HEALTH™
Protecting Life's Potential

**Valent Health is
an ISO 9001 Certified Company**

valenthealth.com

Valent Health
1910 Innovation Way, Suite 100
Libertyville, Illinois 60048

VECTOPRIME and BIOFUSE are registered trademarks of Sumitomo Biorational Company LLC. The VALENT HEALTH logo is a registered trademark of Sumitomo Biorational Company LLC. CYCLONE is a trademark of Cyclone Seeder Company. ORTHO and WHIRLYBIRD are registered trademarks of OMS Investments Inc. MARUYAMA is a registered trademark of Maruyama US, Inc. STIHL is a registered trademark of Andreas Stihl AG & CO KG. HERD is the trademark of Kasco Manufacturing Co., Inc.

© 2026 Valent Health

